Financial Performance - The company's operating revenue for 2020 was CNY 375,433,111.72, representing a year-over-year increase of 5.71% compared to CNY 355,159,969.62 in 2019[21]. - Net profit attributable to shareholders for 2020 was CNY 84,745,713.59, reflecting a 14.54% increase from CNY 73,988,897.22 in 2019[21]. - The company's total assets at the end of 2020 reached CNY 1,292,250,751.64, a significant increase of 140.21% from CNY 537,961,728.25 in 2019[21]. - Basic earnings per share for 2020 were CNY 1.09, up 2.83% from CNY 1.06 in 2019[22]. - The company's total profit reached CNY 99,853,025.37, an increase of 14.45% compared to the previous year[107]. - The operating cost increased to CNY 75,964,151.22, reflecting a significant rise of 31.10% from the previous year[109]. - The company's comprehensive gross profit margin for 2020 was 79.77%, a decrease of 3.92 percentage points compared to 2019[111]. - The revenue from self-produced products was CNY 336,619,815.39, with a gross margin of 83.92%, down by 2.81 percentage points year-on-year[112]. - The revenue from purchased products was CNY 33,226,096.32, with a gross margin of 39.50%, decreasing by 7.64 percentage points compared to the previous year[112]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased to 7.39% in 2020 from 6.15% in 2019, indicating a focus on innovation[22]. - The company achieved a total R&D investment of ¥27,732,236.90, representing a 26.87% increase compared to the previous year[58]. - R&D investment accounted for 7.39% of total operating revenue, up from 6.15% in the previous year, indicating a 1.24 percentage point increase[58]. - The company has a high-quality R&D team of over 110 members, accounting for 21.44% of total employees, and has established an effective innovation mechanism to enhance its technological capabilities[72]. - The company is focused on improving the efficiency and quality of work for pathologists through innovative solutions[62]. Product Development and Market Position - The company operates in the high-tech pharmaceutical sector, focusing on medical technology and automation[13]. - The company has established three major technology platforms for in vitro diagnostics, covering cytology, molecular diagnostics, and immunodiagnostics[32]. - The company has developed several core technologies, including sedimentation liquid-based cytology and real-time fluorescence PCR preparation technology, enhancing its product offerings[32]. - The company has developed a PCR reagent kit capable of detecting 18 HPV subtypes simultaneously with high sensitivity and low amplification bias[51]. - The company has launched a series of automated pathology diagnostic instruments, including a fully automated sample processing machine and a fully automated immunohistochemistry staining machine[53]. - The company has developed a comprehensive cervical cancer screening solution that integrates cytological and HPV testing methods, significantly improving specimen satisfaction and detection rates compared to traditional methods[68]. Market Strategy and Expansion - The company aims to become a leading player in the domestic in vitro diagnostic field by focusing on product innovation and expanding its product application range[140]. - The marketing strategy includes building a direct sales network across various levels of medical institutions and expanding into rapidly growing grassroots hospitals and third-party testing institutions[143]. - The company will explore international markets when conditions are favorable to achieve global product reach[143]. - The company has established a marketing network covering nearly 1,800 medical institutions across 31 provinces, with direct sales accounting for over 60% of its sales model[35]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not indicated any special arrangements in corporate governance[8]. - The company will ensure that related party transactions are conducted at fair market prices to protect the interests of shareholders[169]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the inability to keep up with industry trends in product development, which could impact future growth potential[92]. - The company is exposed to risks from increased competition in the in vitro diagnostics market, with new entrants and existing competitors enhancing their capabilities[101]. - The company acknowledges the risk of core technology leakage and the potential loss of key technical personnel, which could impact future development capabilities[94]. Dividend Policy - The company plans to distribute a cash dividend of 2.80 RMB per 10 shares, totaling approximately 26,135,200 RMB, which represents 30.84% of the net profit attributable to shareholders for 2020[6]. - The profit distribution plan was approved by the board and supervisory committee, with independent directors expressing clear agreement[151]. - The company has a profit distribution policy that mandates at least 20% of the distributable profit to be allocated for cash dividends if the audited net profit is positive[147]. Financial Position and Assets - The company achieved a total asset of 1,292.25 million yuan and a net asset of 1,167.97 million yuan by the end of the reporting period, indicating a solid financial position[82]. - The company's cash and cash equivalents increased significantly to ¥635,270,871.63, representing 49.16% of total assets, up from 15.93% in the previous period, a growth of 641.29%[129]. - The company's receivables from accounts rose to ¥184,749,414.65, accounting for 14.3% of total assets, an increase of 9.04% compared to the previous period[130]. - The company's fixed assets reached ¥54,496,950.86, representing 4.22% of total assets, with a notable increase attributed to fundraising for R&D investments[130].

Financial Performance - Operating revenue for the first nine months increased by 5.75% year-on-year, amounting to CNY 264,639,058.28[6] - Net profit attributable to shareholders grew by 10.18% year-on-year, reaching CNY 66,376,047.17[6] - Total operating revenue for Q3 2020 reached ¥119,818,695.61, a 27.1% increase from ¥94,348,622.56 in Q3 2019[30] - Net profit for Q3 2020 was ¥33,639,133.69, representing a 17.4% increase compared to ¥28,543,221.50 in Q3 2019[31] - The total profit for Q3 2020 was ¥30,201,030.22, up from ¥26,093,850.01 in Q3 2019, reflecting a growth of 8.1%[35] - The company reported a total comprehensive income for Q3 2020 of ¥33,639,133.69, compared to ¥28,543,221.50 in Q3 2019, indicating a growth of 17.4%[36] Assets and Liabilities - Total assets increased by 130.41% year-on-year, reaching CNY 1,239,495,993.32[6] - The total assets of the company stood at ¥1,239,495,993.32, up from ¥537,961,728.25 year-over-year[24] - Total liabilities decreased to ¥89,882,155.46 from ¥93,334,074.16, reflecting improved financial stability[24] - Total liabilities as of Q3 2020 amounted to ¥119,279,769.51, up from ¥105,597,668.44 in the previous year[28] - Total current liabilities were reported at ¥53,065,135.17, a decrease from ¥57,761,738.81, indicating improved liquidity management[23] Shareholder Information - Net assets attributable to shareholders rose by 159.34% compared to the previous year, totaling CNY 1,149,601,367.46[6] - The total number of shareholders reached 10,537 by the end of the reporting period[12] - The top shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[12] - Shareholders' equity increased significantly to ¥1,149,613,837.86 from ¥444,627,654.09, showcasing strong retained earnings and capital growth[24] Cash Flow - The net cash flow from operating activities decreased by 27.88% year-on-year, totaling CNY 41,442,592.34[6] - Cash flow from financing activities showed a net increase of CNY 648,008,526.05, a significant improvement from a net outflow of CNY -19,219,250.00 in Q2 2020[39] - The cash flow from operating activities for the first three quarters of 2020 was ¥271,986,515.96, slightly down from ¥273,345,531.90 in the same period of 2019[37] Research and Development - R&D expenditure as a percentage of operating income increased by 1.18 percentage points to 6.60%[7] - Research and development expenses for Q3 2020 totaled ¥6,188,761.20, an increase of 16.4% from ¥5,311,490.58 in Q3 2019[30] - Research and development expenses for Q3 2020 were ¥4,513,963.91, an increase of 52.2% from ¥2,964,224.35 in Q3 2019[35] Investment Activities - The company reported a net cash flow from financing activities of ¥648,008,526.05, a significant increase compared to the previous year[16] - The company has invested ¥102,233,595.00 in construction projects, up from ¥81,192,580.35, highlighting ongoing expansion efforts[23] - The company received CNY 649,520,526.05 from investment in Q3 2020, compared to CNY 1,700,000.00 in the previous quarter[39] Market Strategy - The company is focused on expanding its market presence and enhancing product development strategies[18] - The company plans to continue expanding its market presence and invest in new product development[30] Other Financial Metrics - Basic and diluted earnings per share increased by 5.81% to CNY 0.91[7] - The weighted average return on net assets decreased by 1.92 percentage points to 12.53%[7] - Other income increased by 90.34% to ¥1,090,906.00, attributed to government subsidies and VAT refunds[16]